Advertisement

Fall 20: Spätschäden – 58 Jahre, ♀, DM Typ 1, drohende Dialyse

  • Lars Kihm
Chapter

Zusammenfassung

Eine 58-jährige Patientin, jetzt einem Kreatinin von 4,5 mg/dl, einem Harnstoff von 150 mg/dl, Übelkeit und Erbrechen, einem Body Mas Index von 28, Blutdruck von 150/95 mm Hg, einem LDL von 180 mg/dl, einer Makroalbuminurie und einem HbA1c von 8,0 %. Wie kann man die Dialyse hinauszögern?

Literatur

  1. ACCORD Study Group, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. New Engl J Med 362(17):1575–1585.  https://doi.org/10.1056/NEJMoa1001286CrossRefGoogle Scholar
  2. ACCORD Study Group (2014) Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. Lancet Diabetes Endocrinol 2(10):793–800.  https://doi.org/10.1016/S2213-8587(14)70155-XCrossRefGoogle Scholar
  3. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellstrom B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Gronhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R, Investigators S (2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377(9784):2181–2192.  https://doi.org/10.1016/S0140-6736(11)60739-3CrossRefPubMedPubMedCentralGoogle Scholar
  4. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, Investigators RS (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New Engl J Med 345(12):861–869.  https://doi.org/10.1056/NEJMoa011161CrossRefPubMedGoogle Scholar
  5. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. New Engl J Med 329(20):1456–1462.  https://doi.org/10.1056/nejm199311113292004CrossRefGoogle Scholar
  6. The DCCT/EDIC Research Group, Boer IH de, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Zinman B (2011) Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. New Engl J Med 365(25):2366–2376.  https://doi.org/10.1056/NEJMoa1111732CrossRefGoogle Scholar
  7. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E, German D, Dialysis Study I (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New Engl J Med 353(3):238–248.  https://doi.org/10.1056/nejmoa043545CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Abteilung Innere Medizin IMedizinische UniversitätsklinikHeidelbergDeutschland

Personalised recommendations